Menu
Search
|

Menu

Close
X

CytomX Therapeutics Inc CTMX.OQ (NASDAQ Stock Exchange Global Select Market)

24.58 USD
-- (--)
As of Jun 22
chart
Previous Close 24.58
Open --
Volume --
3m Avg Volume 172,103
Today’s High --
Today’s Low --
52 Week High 34.98
52 Week Low 13.11
Shares Outstanding (mil) 38.96
Market Capitalization (mil) 957.58
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
14
FY17
72
FY16
15
FY15
8
EPS (USD)
FY18
-0.401
FY17
-1.842
FY16
-1.626
FY15
-1.237
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.14
Price to Sales (TTM)
vs sector
12.91
8.17
Price to Book (MRQ)
vs sector
19.26
4.30
Price to Cash Flow (TTM)
vs sector
--
22.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.55
LT Debt to Equity (MRQ)
vs sector
0.00
13.12
Return on Investment (TTM)
vs sector
-33.98
13.10
Return on Equity (TTM)
vs sector
-123.20
15.09

EXECUTIVE LEADERSHIP

Hoyoung Huh
Chairman of the Board, Since
Salary: --
Bonus: --
Sean McCarthy
President, Chief Executive Officer, Director, Since
Salary: $450,000.00
Bonus: --
Debanjan Ray
Chief Financial Officer, , IR Contact Officer, Since 2017
Salary: --
Bonus: --
Cynthia Ladd
Senior Vice President, General Counsel, Since 2015
Salary: --
Bonus: --
W. Michael Kavanaugh
Chief Scientific Officer and Head - Research and Non-Clinical Development, Since 2015
Salary: $395,117.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

151 Oyster Point Blvd Ste 400
SOUTH SAN FRANCISCO   CA   94080-1910

Phone: +1650.5153185
Site: cytomx.com/

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

SPONSORED STORIES